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Zusammenfassung
Die überarbeitete 11. Auflage des Manuals mit Empfeh-
lungen zur Diagnostik, Therapie und Nachsorge bei Pa-
tientinnen mit Mammakarzinom aus der Schriftenreihe
des Tumorzentrums München (TZM) ist ein exzellentes
Beispiel für eine regionale Handlungsanweisung für die
tägliche Praxis, die zwar auf den nationalen und interna-
tionalen Leitlinien basiert, diese aber nicht ersetzt. Durch
unzählige Ergänzungen und Überarbeitungen innerhalb
von 10 Auflagen ist das «blaue Tumormanual Mamma-
karzinom» zu einem praxisnahen Nachschlagewerk ge-
reift, das bundesweit auf den Schreibtischen von Ärztin-
nen und Ärzten zu finden ist und damit eine Bedeutung
erlangt hat, die weit über das Verbreitungsgebiet des
TZM hinausgeht. Die Reputation dieses Manuals gründet
zum einen auf der Fachkompetenz der einzelnen Auto-
rInnen und Projektgruppenmitglieder. Die große Stärke
der Projektgruppe liegt aber sicherlich im breiten Spek-
trum der Expertise von über 180 ExpertInnen aller er-
denklichen Fachdisziplinen, deren interdisziplinärer Aus-
tausch auch bei der aktuellen Überarbeitung wieder zu
einem weit über München hinaus beachteten Ergebnis
geführt hat. Dieser Artikel fasst einige eigene Standpunk-
te der Projektgruppe des TZM zur Datenerfassung, zur
Prävention, zur adjuvanten Systemtherapie und zur
Nachsorge exemplarisch zusammen.
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Summary
The revised 11th edition of the Manual of Recommenda-
tions for the Diagnosis, Therapy, and Follow-Up of Pa-
tients with Breast Cancer of the publications series of the
Tumor Center Munich (Tumorzentrum München, TZM) is
an excellent example of a regional hands-on publication
which, while based on national and international guide-
lines, does not replace these. By virtue of countless addi-
tions and revisions in the course of 10 editions, the ‘blue
tumor manual for breast cancer’ has matured into a
hands-on reference work which throughout Germany
has found its place on the desks of physicians, and has
thus gained a reputation reaching far beyond the TZM.
The reputation of this manual is on the one hand found-
ed on the professional competence of the individual au-
thors and project group members. The great strength of
the project group, however, surely lies in the broad spec-
trum of expertise of more than 180 experts of all kinds of
specialties, whose continuing interdisciplinary exchange
in the course of the present revision has again led to a
result which is arousing interest far beyond Munich. This
article summarizes some of the TZM project group’s own
positions on data collection, prevention, adjuvant sys-
temic therapy, and follow-up treatment in an exemplary
fashion. 
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Introduction
The revised 11th edition of the Manual of Recommendations
for the Diagnosis, Therapy, and Follow-Up of Patients with
Breast Cancer of the publications series of the Tumor Center
Munich (Tumorzentrum München, TZM) [1] is an excellent
example of a regional hands-on publication which, while
based on national and international guidelines, does not re-
place these. By virtue of countless additions and revisions in
the course of 10 editions, the ‘blue tumor manual for breast
cancer’ has matured into a hands-on reference work which
throughout Germany has found its place on the desks of
physicians, and has thus gained a reputation reaching far be-
yond the TZM. This article summarizes some of the TZM pro-
ject group’s own positions on data collection, prevention, adju-
vant systemic therapy, and follow-up treatment in an exem-
plary fashion. 
Position on Data Collection: Epidemiological Data from
the Munich Cancer Registry 
The Munich Cancer Registry (Tumor-Register München,
TRM) [1] collects clinical data from the Munich area in exem-
plary fashion, and evaluates these at regular intervals in the
sense of a modern ‘benchmarking’ for medical quality control.
The TRM’s catchment area has repeatedly been enlarged
since its foundation in 1978. Starting from the Munich munici-
pal area, documentation was continually extended to the sur-
rounding administrative districts. As a result, there is the ‘old
catchment area’ of 1978 with 2.3 million inhabitants from Mu-
nich city and the administrative districts of Dachau, Ebers-
berg, Erding, Freising, Fürstenfeldbruck, München-Land
(Greater Munich Area), and Starnberg. About 10 years later
(i.e. around 1988), complete coverage of the population in this
area with regard to breast cancer patients was by and large
achieved. Since 1994, all pathological findings in the region are
fully transmitted to the TRM. Some up-to-date epidemiologi-
cal parameters for Germany are displayed in table 1. The re-
sults and estimates have been compiled from various sources. 
In 1998, the Law on the Implementation of the Cancer Reg-
istry Law (Gesetz zur Ausführung des Krebsregistergesetzes,
AGKRG) came into effect. In the AGKRG, processing of
death certificates by the TRM was for the first time made
legally binding, starting 1 January 1998. This regulation was
also adopted in the Bavarian Cancer Registry Law (Bay-
erisches Krebsregistergesetz, BayKRG). In the BayKRG,
which was passed in the year 2000, region-wide registration of
cancer cases in all of Bavaria beginning with the year 2002 was
enacted, which for the TRM led to an expansion of the catch-
ment area so that it now covers 3.84 million inhabitants as
 opposed to 2.3 million. The new catchment area includes, in
addition to the previous area, the administrative districts of
Weilheim-Schongau, Garmisch-Partenkirchen, Bad Tölz-Wolf-
ratshausen, Miesbach, Rosenheim, Berchtesgaden, Traunstein,
Altötting, Mühldorf am Inn, and Landshut. The end-of-2005
amendment to the BayKRG stipulates a re-organization of
the catchment areas with effect from 1 January 2007 insofar as
the entire government district of Upper Bavaria as well as the
administrative districts of Landshut and Greater Landshut
Region are to be part of the TRM catchment area. The num-
ber of inhabitants thus rises to 4.4 million. Under www. tumor-
register-muenchen.de (see also www.krebsinfo.de), data on in-
cidence and mortality as well as tumor-specific evaluations
with basic statistics, survival analyses, and special analyses are
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Table 1. Basic epidemiological figures for Germany (Engel et al. [5])
Incidence
Annual incidence in Germany, % 2002 26.8
Absolute incidencea (per 100,000) 2002 126.8
Proportion of all new cancer casesa
(per 100,000) 1998–2002e 73.6
Raw incidence (RKI)b (per 100,000) 1998–2002e 154.7
Incidence (RKI) world standard (ASR)b
(per 100,000) 1998–2004e 86.7
Raw incidence (TRM)c 1998–2004e
Incidence (TRM) world standard (ASR)c 1998–2004e
Age at onset, years
Averagec 1998–2005 63.4
10% younger than/10% older thanc 1998–2005 44.7/82.7
Average survival period (cancer-related death), years
M0 (TRM)c 1978–2005 6.4
All, including M1 (TRM)c 1978–2005 5.6
Survival rate, %
5-year (overall/relative)c 1998–2005 78.4/85.4
10-year (overall/relative)c 1978–2005 59.8/70.6
15-year (overall/relative)c 1978–2005 46.6/60.4
Deaths
Deaths from breast cancer in Germany, n 2005 17,455
Deaths due to cancer in Germanyd, % 2005 17.6
RKI = Robert Koch Institute; ASR = age standardized rate (here: world
standard); TRM = Tumor-Register München (Munich Cancer Registry).
aSociety of Epidemiologic Cancer Registries in Germany (Gesellschaft
epidemiologischer Krebsregister in Deutschland e.V., GeKiD) in coopera-
tion with the RKI [6]. The new cases are an estimate for the year 2002.
bThe raw incidence indicates the number of new cases per 100,000 women
occurring in a year. Here, the averaged values from 1998 to 2002, which is
the latest year currently available, are indicated [3].
cThe incidences (raw, world standard) are averaged values of the annual
cohorts of 1998–2004 in the TRM catchment area: Munich and bordering
administrative districts, from 2002 additionally administrative districts
from almost all of Upper Bavaria. The different values of age at onset are
averaged values of the 1998–2005 annual cohorts. Survival probabilities
have been determined for the 5-year survival rates from the annual dis-
ease cohorts from 1998 to 2005, for the 10- and 15-year survival rates from
annual cohorts from 1978 to 2005. All deaths are included in observed or
overall survival, while relative survival is an estimate for tumor-specific
survival. Relative survival is calculated by dividing observed (overall) sur-
vival by expected survival and thus estimating tumor-specific survival [4].
Expected survival describes the survival rate of a normal population co-
hort of identical composition with respect to age and gender.
dFederal Office of Statistics (Statistisches Bundesamt): causes of death in
Germany 2005 [2]. 
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made available online. Furthermore, annual reports as well as
further information on the TRM are to be found here (table 2,
fig. 1).
Position on Prevention 
The TZM breast cancer project group has developed practical
recommendations for affected patients on the basis of existing
data from prospective randomized studies (tables 3 and 4).
Prevention of diseases with high epidemiological frequency
has increasingly moved into the focus of health policy consid-
erations and become part of physicians’ professional activities.
All in all, increasing efforts toward early diagnosis and pre-
vention on the part of doctors and also of the financing insti-
tutions have become evident over the course of the last years.
Education on preventive measures, first and foremost of
women at high risk, has been intensified and is slowly finding
its place in practical clinical implementations (WHO Global
Strategy on Diet and Physical Activity: key policy recommen-
dations; www.brustkrebsvorbeugen.de).
The promising results of the present breast cancer prevention
trials show that prevention is possible either by avoiding car-
cinogenesis, or through a form of early therapy. Future trial
results will show which substance in practice is most effective
and has the least adverse side effects. The dilemma of having
to treat a great number of healthy women in order to prevent
disease occurrence in a few, will, however, remain unchanged.
Selective prevention specifically targeting individuals is, as of
yet, not possible. The influence of breast cancer prevention
on overall survival has not yet been demonstrated. It follows
that, notwithstanding all positive intentions, a specific ap-
praisal of risks and benefits with respect to the individual case
in interdisciplinary cooperation, following extensive patient
education, must be ensured. Drug prevention as well as surgi-
cal prevention should only be carried out under clinical trial
conditions at well-established centers. At present, the IBIS II
trial is open for postmenopausal women in Germany with 
increased risk of breast cancer. Comprehensive information
for physicians involved in the care of such patients and 
for women seeking advice are available under www.
brustkrebsvorbeugen.de.
Position on Adjuvant Therapy Recommendations 
With the exception of patients with cancer in the earliest
stages (so called low-risk group according to St. Gallen 2007),
adjuvant systemic therapy is, in principle, indicated. 
Endocrine Therapy
Endocrine therapy is always indicated in hormone-sensitive
(hormone receptor-positive) tumors, but side effects should
also be taken into consideration in tumors with doubtful hor-
mone sensitivity. Endocrine therapy can be dispensed within
the low-risk group, as a decisive advantage in terms of life ex-
pectancy is not to be expected. In the final analysis, even the
low rate of side effects can, for example, lead to additional
therapy-related deaths at a similar rate as tumor-related
deaths would be prevented. Endocrine therapy in this group
serves above all to prevent contralateral cancer growths and
local recurrence. Endocrine therapy should be started after
concluding chemotherapy if this is indicated, it can, however,
be initiated either simultaneously with radiotherapy or after
conclusion of radiotherapy. Menopause status is the essential
distinguishing criterion for the type of endocrine therapy. 
Postmenopause
According to the present state of knowledge, there are 2 options
in the postmenopause: the hitherto accepted standard tamoxifen
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Fig. 1. Munich Cancer Registry: breast cancer, relative survival in rela-
tion to pT (n = 22,541); relative survival is an estimate for tumor-specific
survival (Engel et al. [5]).
Table 2. Proportion of classical prognostic factors in relation to pT cate-
gory for the annual cohorts from 1998 to 2004 (n = 13,091) of the Munich
Cancer Registry (Engel et al. [5])
pT Patients, Average pN G3, % Receptor- Primary
category % age, years positive, negative,  M1, %
% %
pTis 6.3 58.8 0 – 21.4 0
pT1 52.4 59.6 24.9 23.6 11.5 1.3
pT1a 2.9 58.5 9.7 18.2 14.1 0.8
pT1b 12.0 59.7 15.5 14.5 9.8 0.9
pT1c 37.5 59.8 29.5 26.5 11.5 1.5
pT2 32.5 62.9 49.7 44.9 16.3 4.1
pT3 3.8 64.5 68.2 52.0 20.4 9.2
pT4 5.0 72.2 71.3 54.1 14.5 25.6
Overall 100 63.4 35.3 33.8 14.1 3.7
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(20 mg/day), and application of an aromatase inhibitor. Accord-
ing to guidelines, almost every postmenopausal patient should
be offered an aromatase inhibitor. The optimal therapy scheme
when initiating endocrine therapy has not yet been finally clari-
fied: besides up-front therapy with an aromatase inhibitor, se-
quential therapy with tamoxifen for 2–3 years followed by an
aromatase inhibitor is also evidence-based. Therapy exclusively
with tamoxifen is an option for low-risk patients or when con-
traindications apply. Duration of adjuvant endocrine therapy is 
5 years in all. After completing a 5-year course of tamoxifen
therapy, extended adjuvant therapy with an aromatase inhibitor
can be useful, particularly in nodal-positive patients. 
Premenopause
In women who will not receive chemotherapy (see below), a
combination of gonadotropin-releasing hormone (GnRH)
analogues (or other forms of ovarian ablation) and tamoxifen
should be applied. When chemotherapy is applied, endocrine
standard therapy is sequential therapy with tamoxifen
(20 mg/day over 5 years). Following chemotherapy, additional
therapy with GnRH analogues is not standard, but may be
considered upon completing chemotherapy in very young
women under the age of 40 or when premenopausal hormone
levels persist. Therapy with GnRH analogues should be car-
ried out for at least 2 years (5 years at most). Oncological data
on the effectiveness of aromatase inhibitors in premenopause
are presently not yet available. Exclusive administration of
aromatase inhibitors in premenopausal patients is contraindi-
cated. If, in well justified individual cases (e.g. drug intoler-
ance), therapy is to be switched from tamoxifen to an aro-
matase inhibitor, or if a hitherto amenorrheic perimenopausal
patient reverts to premenopausal conditions under therapy
with aromatase inhibitors, additional application of GnRH
analogues is mandatory. 
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General recommendation
Treatment goal
Greatest clinical benefit with less adverse side  
effects
Tamoxifen in combination with hormone 
 replacement therapy (HRT)
Tamoxifen in combination with or followed by 
other drugs with potential preventive effect
Proven effect on overall survival
Estimated overall survival and cost-benefit 
analysis in high-risk groups
Comment
women with risk of breast cancer > 1.66% in the next 5 years 
(20 mg/day for 5 years) for risk reduction
reduction of short term risk of developing breast cancer
premenopausal, hysterectomized, and younger women (lower risk of
thrombosis)
not recommended outside of clinical studies due to unreliable data regar-
ding a possible increase in breast cancer incidence and long term adverse
effects; the European studies (Veronesi, Powles) permitted HRT – with
opposite effects; in the HOT trial (Italy; Decensi), low-dose tamoxifen 
(5 mg) is combined with HRT
no data available
no data available (has up to now not been defined as study end point);
the IBIS I trial shows increased mortality due to other causes of death in
the tamoxifen arm with respect to the comparison arm
according to model calculations in the group with atypical ductal hyper-
plasia, an increase in life expectancy of 202/89/45 days is expected when
tamoxifen treatment is begun at age 35/50/60 respectively; greatest effec-
tiveness is to be expected with a risk calculated according to Gail > 5%,
in the group with lobular carcinoma in situ or more than 2 first-degree
relatives with breast cancer, if treatment is started before the age of 50; in
this case, cost would be in balance with benefit
tamoxifen treatment recommendations should be voiced in the context
of the overall process of counseling women with increased risk of breast
cancer while taking into account benefit/risk considerations; the drug is
approved for the indication of breast cancer prevention exclusively in the
USA; in Germany, preventive drug therapy is to be recommended only
under clinical trial conditions
Table 3. Summary
and recommendations
on breast cancer
 prevention with 
tamoxifen (Wolf et al.
[6])
Drug/group of drugs Current recommendations
Aromatase inhibitors only under trial conditions: anastrozol presently tested against placebo in post
menopausal women with (moderately to strongly) increased risk of breast cancer in 
Europe and Australia/New Zealand
Selective estrogen receptor to date only tested under trial conditions against tamoxifen (results of STAR, MORE,
modulator (SERM) raloxifene CORE trials available)
Retinoids only under trial conditions
COX-2 inhibitors only under trial conditions (at present not to be recommended in general)
Beta-carotene not recommended, tested as exclusive therapy or in combination without proof of 
preventive effect
Table 4. Summary
and recommenda-
tions on breast cancer
prevention: further
drugs or groups of
drugs (Wolf et al. [6])
100_107_03009_janni:100_103_03009_janni  09.05.2008  10:16 Uhr  Seite 103
Chemotherapy
Indication
Evidence from data of randomized studies on adjuvant
chemotherapy mostly includes patients under 70 years of age
only. More recent studies often no longer have an age limit by
date of birth but rather use biological age and comorbidities
as orientation criteria. For patients over 65 years of age, fur-
ther trials are presently being conducted (e.g. ICE) to assess
the value of adjuvant chemotherapy in elderly patients.
Chemotherapy is generally considered indicated in receptor-
negative tumors.
Patients with the following indications should in principle be
offered chemotherapy (no chemotherapy only on grounds of
clear contraindications or refusal): i) axillary lymph nodes af-
fected; ii) doubtful hormone sensitivity if the tumor does not
belong to the low-risk category; iii) age under 35 years (in spe-
cific cases also under 40).
Chemotherapy should be offered liberally and be carefully
discussed with the patient when the following conditions
apply: i) lymph nodes affected, no unfavorable tumor biology,
good hormone sensitivity and age over 60 years; ii) nodal-neg-
ative patients with unfavorable tumor biology (e.g. G3, inva-
sion of blood vessels, HER2 overexpression or increased pro-
teolytic factors uPA or PAI-1); iii) premenopausal women
whose lymph nodes are not affected and who do not belong to
the ‘low risk group’. Chemotherapy may be offered to patients
in the following situation: nodal-negative postmenopausal pa-
tients without unfavorable tumor biology who do not belong
to the low-risk group.
Taking into account the above mentioned cases, chemothera-
py can be abstained from in the following situations: i) larger
G1 tumors (2–5 cm) with negative lymph nodes and favorable
tumor biology (hormone-sensitive, no blood vessel invasion,
no HER2 overexpression, tubular histology, low uPA/PAI-1),
especially if the clinical course points to a long disease history
(protracted tumor with slow kinetics); ii) G2 tumors (1–2 cm)
with favorable auxiliary criteria (see above). No chemothera-
py is indicated in cases belonging to the low-risk group ac-
cording to St. Gallen 2007. 
Trastuzumab
Adjuvant 1-year trastuzumab therapy following primary sys-
temic or adjuvant chemotherapy is standard in HER2-positive
breast cancer (HER2 3+ or fluorescent in situ hybridization
(FISH)-positive). It is approved regardless of age, nodal status,
or time elapsed since primary surgery. Indication should be as-
sessed independent of nodal status or age of the patient, pro-
vided there is no contraindication to the planned therapy. Ac-
cording to the present state of knowledge, therapy can be
started together with the taxane chemotherapy or carried
through completely after chemotherapy. 
Off-Label Use
On the basis of experiences with trastuzumab, the question of
off-label use repeatedly arises in adjuvant therapy when ther-
apy procedures substantiated by significant phase III study re-
sults and recommended in guidelines have not yet been ap-
proved. The following procedure is recommended for physi-
cians planning such therapy: i) approaching an interdiscipli-
nary tumor consultation service as is run by most larger clinics
today; ii) alternatively, obtaining a second (or third if neces-
sary) opinion from colleagues with experience, especially in
adjuvant therapy studies, in order to have the indication con-
firmed by several physicians; iii) where necessary, conferring
with the respective health insurance to seek confirmation that
costs will be met and letting the patient fetch such confirma-
tion from her health insurance. According to experienced
lawyers, it is controversial whether the physician should apply
for such confirmation himself, as he would find himself in a
dilemma in the case of refusal: by his application he would
have shown that despite the fact that it is not officially ap-
proved, he considers the therapy to be indicated/necessary
from a medical point of view so that failure to implement it
could even represent medical malpractice. Failure on the part
of health insurances to pay for a particular therapy, however,
does not absolve the physician from his duty to provide ap-
propriate, medically indicated therapy (in analogy to emer-
gency therapy for uninsured persons). Off-label use is, accord-
ing to the current jurisdiction by the Federal Social Court, jus-
tified and may be refunded by health insurances if it is a case
of a potentially life-threatening disease, if data from large
phase III studies are available, or if there are no appropriate
alternative therapy strategies available. 
Position on Follow-Up Treatment 
The TZM’s breast cancer project group, while recognizing the
(insecure) evidence status, acknowledges the validity of the of-
ficial follow-up treatment guidelines of the German Cancer
Society (Deutsche Krebs-Gesellschaft, DKG) and the Ameri-
can Society of Clinical Oncology (ASCO). The project group
does, however, on account of an outdated data basis and prac-
tical experiences, see the need for a scientific reassessment of
the scope of follow-up therapy with respect to content as well
as to scaling of intervals under the conditions of modern diag-
nostic and therapeutic possibilities. 
‘Follow-up treatment of cancer patients is a physician’s job
and is based on up-to-date knowledge of tumor biology.’ This
is the first sentence of the result statement of a consensus con-
ference which met in February 1995 in Berlin for discussions
on content and frequency of follow-up treatment in symptom-
free affected persons who had undergone breast cancer
surgery. The restrictive follow-up treatment recommendations
issued in the 1990s were based on the meta-analyses published
in 1994 and 1999, which, using technical diagnostics, had failed
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to deliver proof of increased life expectancy despite improved
early diagnosis in up to 10%. No more systematic analyses
have been carried out or published since then, or could even
be implemented due to a lack of willingness on the part of the
patients to undergo randomization. 
The follow-up recommendations valid since the 5th edition
of the TZM manual (1994) are still congruent with the cur-
rent ASCO guidelines [2], and in the same form also consti-
tute the content of the new evidence based (S3) guideline of
the DKG for Germany (table 5). The principle still applies
that (apart from mammography and breast sonography) no
routine machine-aided diagnostics, including laboratory tests
and tumor markers, should be carried out in symptom-free
affected persons, as no benefit has been proven for these
measures. For follow-up of symptom-free women, detailed
history and a thorough physical examination, counseling as
well as diagnosis and, if applicable, treatment of therapy-asso-
ciated side effects is recommended as the primary duty of a
physician. Sonography of the operative field and lymphatic
drainage can supplement physical examination following
breast conserving therapy as well as ablation. Other expert
opinions which deviate from these results of systematic evalu-
ation of world literature and, albeit without sufficient evi-
dence, call for an extended follow-up program, have also
been publicized. Special tests may become necessary in the
course of follow-up when certain drugs (e.g. tamoxifen, aro-
matase inhibitors, bisphosphonates) are administered. In
these cases, regular laboratory tests (especially liver and kid-
ney status, blood sugar, calcium), gynecological examinations
and, before beginning tamoxifen therapy and in the event of
visual impairment, check ups by an ophthalmologist are to be
recommended. Especially after a lengthy tamoxifen therapy,
isolated cases of uterine cancer on the basis of endometrial
hyperplasia occur. If anthracyclines are administered as
pretherapy, the possibility of subsequent cardiomyopathy
should be considered (with prescription of echocardiography
or multiple-gated acquisition (MUGA) scan), especially in
cases of a high cumulative dose. Further rare after-effects are
degenerative central nervous system (CNS) diseases with
cerebral dysfunction and secondary cancers such as leukemia,
lymphomas, or sarcomas in the irradiated area.
An important component of this program is the women’s self-
observation and self-examination of the operated region as
well as the contralateral breast. Women should be encouraged
at every follow-up consultation to seek their doctor’s advice
immediately in the event of any change or complaint, and not
to wait until the next routine consultation. The intensive, per-
sonal conversation between the oncologically experienced
doctor and his patient, for which no amount of machine-aided
diagnostics can ever be a substitute, must also especially take
into account the woman’s psycho-social situation. Support
must be offered as appropriate. This also includes informing
the patient on her legal rights to medical and psychological re-
habilitation measures, social support (disability certificate, im-
proved exemption from contribution payments, where applic-
able also nursing care services, household help, family help,
self-help groups) as well as to other benefits (physical therapy,
supply with prosthesis, advice on underwear, wig). In the pre-
sent age, with resources scarce and budgets tight, important
physical therapy measures in sufficient quantities are not sel-
dom refused with reference to limited budgets because of the
danger of regress. In such cases, the oncologist in charge is re-
quired, if necessary also by legal means, to ensure provision
appropriate to the patient’s needs, particularly lymph drainage
of sufficient duration and frequency. 
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Clinical follow-up Years following primary therapy
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯
1 2 3 4 + 5 6–10
History, physical examination, information every 3 months every 6 months every 12 months
Self examination every month
All other technical examinations including only in case of clinical suspicion of recurrence and/or metastases
lab tests and tumor markers (exception 
mammography: see below)
Mammograpya Years following primary therapy
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯
1 2 3 4 and following
BCS ipsilateral breast every 6 months every 12 months
BCS contralateral breast every 12 months every 12 months
Mastectomy contralateral breast every 12 months every 12 months
aIf necessary supplemented by sonography in cases of dense corpus mammae, unclear findings in mammography or in order
to depict the axilla.
BCS = Breast conserving surgery.
Table 5. Breast
 cancer follow-up:
 recommendations for
symptom-free women
after completion of
primary breast cancer
therapy (Abenhardt
et al. [7])
100_107_03009_janni:100_103_03009_janni  09.05.2008  10:16 Uhr  Seite 105
Data on Intensified Follow-Up
In the past 10–20 years, recommendations for follow-up of pa-
tients after primary therapy of localized or regional breast
cancer have been published in numerous publications and
leaflets. Most of these assumed an empirical, ‘programmed’
follow-up with a fixed frequency of follow-up consultations
and fixed respective content (e.g. bone scan, chest X-ray,
 abdominal sonography, mammography, and laboratory tests/
tumor markers). Up to this day, there are no data to support
an increase in life expectancy linked to early diagnosis and
treatment of distant metastases. Three effects could potential-
ly justify intensified follow-up treatment: i) improved survival
rate (no evidence to date); ii) increased life expectancy from
time of diagnosis (no evidence to date); iii) improved quality
of life (no clear evidence to date).
In the study by Roselli et al. [2], which was re-evaluated after
10 years in 1999 (without gaining new insights), 1,243 patients
with breast cancer were randomized by 12 Italian centers from
1985 to 1986. All in all, the risk distribution was rather favor-
able (57% postmenopausal, 40.1% pT1, 46.7% pT2, 51.5%
pN0, 48.5% with positive hormone receptors). After 5 years,
31 skeletal metastases (84/53) as well as 10 lung metastases
(28/18) were additionally (and thus earlier) found due to in-
tensified follow-up. In the GIVIO trial [3], a total of 1,441 pa-
tients with breast cancer in 32 Italian centers were prospec-
tively randomized between 1986 and 1988. Although the risk
distribution was the same in both groups, a significant propor-
tion had favorable risk factors overall (57–59% postmeno-
pausal, 56% pN0, 49–51% pT1, 45–48% pT2, only 21–22%
negative hormone receptors). After 3 years, metastatic
growths could at least be detected additionally (and thus earli-
er) in 27 patients (157/130, difference 5%) due to intensified
follow-up (for asymptomatic metastatic growths even 10%
difference). The study was initially designed for a 20% reduc-
tion in tumor-related mortality from 35 to 28%. A mortality of
‘only’ 18–20% was, however, found in both groups in the
study. Due to earlier diagnosis of metastases, the relapse-free
survival of the women in the first study, who received ‘inten-
sive’ follow-up, was shorter. A Cochrane meta-analysis [4]
published in 2005 found a total of 4 utilizable studies – with
the 2 large studies mentioned above taking an absolutely
prominent position – and no significant survival benefit
through intensified follow-up. However, even in this publica-
tion, there is a call for further scientific investigations when
new therapy options are available, along with the interesting
remark that restrictive follow-up can only be implemented
with the consent of sufficiently informed patients. 
The main reason for the absence of an effect on the overall
survival in these studies relevant to the drawing up of guide-
lines, however, could be the fact that in the 1980s and 1990s no
effective therapy was implemented in order to achieve a sig-
nificant survival benefit, or that such did not exist at the time.
In the last decades, new therapy procedures have been devel-
oped that, especially with early and targeted application, can
lead to a significant increase in life expectancy in selected col-
lectives, and in individual cases even to long-term remission: i)
extension of endocrine therapy options by gonadotropin-re-
leasing hormone (GnRH) analogues, aromatase inhibitors,
and new selective estrogen receptor modulators (SERMs); ii)
extension of cytostatic therapy options by the taxane sub-
stance group an other innovative cytostatic drugs (e.g.
capecitabine, gemcitabine, vinorelbin etc.); iii) targeted ‘bio-
logical’ therapy options, especially monoclonal antibodies
such as trastuzumab, but also other substance groups, such as
small molecules; iv) loco-regional therapy procedures, such as
thermoablation, brachytherapy, stereotactic irradiation, and
others, which are successful especially in oligometastatic dis-
ease. These procedures are bound to be especially effective in
tumors of limited expansion with respect to number and vol-
ume, i.e. in a relatively early phase of metastatic growth. Suffi-
cient systematic investigations have not been carried out since
these therapy options were newly developed, or could not be
implemented due to a lack of willingness of the patients to
submit to prospective randomization, so that the regular liter-
ature research prior to updating and drawing up of national
and international guidelines yielded no new knowledge.
The project group is conscious of the fact that in view of the
scientific uncertainty summarized here and the doubtlessly ex-
isting attitude of high expectancy on the part of patients, there
is a broad practice of ‘grey follow-up’ going on which in future
can only be swept aside or substantiated through new, solid
scientific data.
Final Recommendations of the TZM Breast Cancer
 Project Group on Follow-Up Therapy of Breast Cancer
The official guidelines of ASCO and DKG (S3 guideline) rec-
ommend machine-aided diagnostics in breast cancer follow-
up in addition to mammography (on grounds of scientifically
founded negative evidence) only in cases with relevant symp-
toms. The project group acknowledges the validity of the na-
tional (S3 guideline of the DKG) and international (ASCO)
guidelines, it does, however, in view of weak and outdated
data, see the need for a scientific assessment, especially in the
higher UICC stages and particularly with respect to content
and scaling of intervals of follow-up consultations (risk-adapt-
ed follow-up).
Routine follow-up is based on thorough, disease-specific his-
tory, targeted physical examination of the whole body, and
mammography of the affected (in breast conserving therapy)
and the contralateral breast at specific intervals, if necessary in
combination with breast sonography. Follow-up treatment
should be carried out for at least 10 years. Chest X-ray, ab-
dominal sonography, and bone scan are unsuitable as screen-
ing procedures in breast cancer follow-up, but are indicated
without delay when founded suspicion arises. The tumor
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markers CEA and CA15-3 in combination have a scientifically
proven high predictive value, their measurement outside of
scientific studies cannot, however, at present be recommended
as a routine measure due to lack of evidence of an overall sur-
vival benefit. The project group proposes a prospective, non-
randomized, interdisciplinary study within the TZM in order
to clarify these questions. 
Final Comment 
In the present 11th edition of the manual, the authors – and
thus the members of the breast cancer project group in the
TZM – have again succeeded in bringing the manual up to the
newest level of scientific knowledge through numerous up-
dates. Some chapters were thoroughly revised, and in some
places the project group took its own stand on controversial
issues. The reputation of this manual is on the one hand
founded on the professional competence of the individual au-
thors and project group members. The great strength of the
project group, however, surely lies in the broad spectrum of
expertise of more than 180 experts of all kinds of specialties,
whose continuing interdisciplinary exchange in the course of
the present revision has again led to a result which is arousing
interest far beyond Munich. The manual can be ordered via
the office of the TZM (Pettenkoferstraße 8a, 3. Stock, 80336
München, Germany) and can also be obtained online via
tumorzentrum-muenchen.de/fileadmin/manuale/909_Manual_
Mammakarzinome.pdf, or may be purchased from bookstores.
The TZM breast cancer project group is the first project group
to supplement the tumor manual for physicians by issuing a
complementary guide for patients based on the tumor manual
which can be seen online as a test version under tumorzen-
trum-muenchen.de/patientenbereich/ratgeber-test.html, and can
likewise be purchased in bookstores. 
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